Les sociétés de biotechnologies

Biotech companies
**Activity**

Affilogic is a privately-owned biotechnology company (SME) incorporated in Nantes early 2010. Affilogic is engaged in design of ideal targeted molecules from functional affinity proteins, Nanofitins. Each Nanofitin module provides a unique function to the assembled molecule through its specific interaction with an element of the body.

**Expertise and Technological Skills**

Affilogic has developed modules (i) inhibiting different cytokines (ii) controlling the residence time in the circulation, (iii) targeting specific receptors (iv) penetrating into tumor cells (v) generating toxicity in the cells thus invaded (vi) recruiting immune system (vii) crossing membranes…

Each module is 20 times smaller than an antibody and hyperstable: resistant to the tumor environment, non-injectable administration (oral, topical, inhalation). Nanofitins are combined with each other or with third party by simple, rapid and proven methods.

**Ongoing Collaboration and References**

Affilogic has implemented a mixed business model: custom discovery and development of Nanofitins with partners, and internal exploration programmes for subsequent licensing. The company has entered into several development and license agreements with pharmaceutical stakeholders such as Sanofi, Takeda, and other major undisclosed companies to fully harness the potential of Nanofitins as therapeutic modalities.

**Sought Opportunities**

The overall strategy of Affilogic is to treat cancer via multiple pathways thanks to multi-functional Nanofitin-based targeted drugs. Two partnering schemes are possible (i) Affilogic can partner with pharmaceutical companies on existing Nanofitin modules currently developed in immuno-oncology that are not encumbered by any exclusivity rights given to a current partner and / or (ii) we can generate new Nanofitins since we also have a platform-based business model.
Activity

Altevax is developing and will bring to market a melanin-based vaccine technology that is an effective treatment for cancer and infectious diseases. This technology, which has been proven in pre-clinical trials and has a patent pending, boosts the immune response to specific antigens with cytotoxic lymphocytes (Cytotoxic T-lymphocytes, CTLs or CD8+ lymphocytes), the body’s most powerful defendants.

Expertise and Technological Skills

The Altevax technology, developed by Prof. Antoine Carpentier at AP-HP, is based on nanoparticles of melanin (an adjuvant) embedding an antigen. Vaccines using such formulations have shown a significantly higher efficacy in triggering cellular immunity than that obtained with currently available adjuvants. Altevax has an exclusive, worldwide licence from AP-HP to develop and market this technology. Prof. Carpentier is the Scientific Director of Altevax.

Ongoing Collaboration and References

Altevax is working in close collaboration with Prof. Carpentier’s lab at AP-HP, as well as Prof. Eric Tartour’s lab (Immunology, HEGP), and Prof. Laurence Motte’s lab (Physics and biomaterials, Université Paris XIII).

Sought Opportunities

The Altevax technology has been proven to treat tumours in mice. The next development step is its pre-approval by health authorities in targeted markets, followed by clinical trials in humans. Altevax intends to build co-development partnerships with pharma companies with expertise and distribution capabilities in immuno-oncology to undertake this process for specific antigens, and to then market the finished vaccine product.
Activity

Founded in 2007, B Cell Design is focused on drug discovery. A spin-off of a CNRS academic laboratory from Limoges University, B Cell Design develops an original concept of mucosal immunotherapy based on a new class of monoclonal antibody. Two molecules are currently in development, a vaccine candidate against HIV and a drug candidate in immunotherapy for the colorectal cancer.

Expertise and Technological Skills

The innovation is based on a platform of transgenic mice, able to generate numerous of highly specific monoclonal antibodies, directly humanized and from a specific isotype. With our solid knowledge on immune mechanisms involved in all the mucosal barriers of our body, B Cell Design develops immunotherapies to cure intestinal mucosa targeted by colorectal cancer or prophylactic vaccine to protect genital mucosa, the first gate of entrance of HIV virus.

Ongoing Collaboration and References

B Cell Design has established collaborations with academics (CNRS, INSERM, University of Limoges, University of Lyon, Saint-Etienne, and University of Strasbourg) and pharma companies (including SANOFI). Several patents as well as international articles have been published following collaborative studies.

Sought Opportunities

With the development of the first monoclonal anti-colorectal cancer IgA, B CELL DESIGN wish for validation of the therapeutic concept of the use of IgA in mucosal targeting therapy. At the completion of the regulatory preclinical phase, we are seeking for a partnership with a pharmaceutical company, with reference expertise for the pursuit of clinical trials in humans and for reaching the market.
CarThera developed the SonoCloud®, an intracranial ultrasound implant that temporarily opens the blood-brain barrier (BBB). By increasing the permeability of the cerebral blood vessels using low intensity pulsed ultrasound, the concentration of therapeutic molecules that reach the brain can be increased by up to seven times and improve dramatically the outcome of chemotherapy and immunotherapy procedures in the treatment of brain diseases.

Expertise and Technological Skills

CarThera has established a multidisciplinary organization with expert engineers for the successful development of breakthrough ultrasound-based medical devices, and lead scientists and physicians for the successful completion of its preclinical and clinical trials for treating brain disorders. The company has a seasoned management team with international scope and expertise in MedTech and BioTech. The intellectual property is covered with a rich patent portfolio.

Ongoing Collaboration and References

CarThera developed collaborations with renowned institutes: LabTau (INSERM lab specialized in therapeutic ultrasound), UPMC and AP-HP for clinical developments, ICM and CEA for preclinical trials, IM2A for exploratory studies in Alzheimer. Moreover, neurosurgeon, neurologists and neurooncologists from the most prestigious French and American hospitals (MD Anderson, Northwestern Hospital and UCSF) accompany the team at CarThera and share their knowledge and experience.

Sought Opportunities

CarThera’s hypothesis is that BBB opening with SonoCloud® will increase brain penetration of immunotherapies and will help at boosting immunity in the brain. SonoCloud® device may notably be used with investigational or commercialized immunotherapies with the goal to control brain disease with the same magnitude as for systemic disease. CarThera is thus interested in entering collaborations with pharmaceutical companies or biotech interested in evaluating the combined use of their agents with its SonoCloud® device.
Activity

ElsaLys Biotech is a biotech company that designs and develops “best-in-disease” therapeutic antibodies targeting tumors and their immune and/or vascular microenvironment. By restoring the ability of immune cells to recognize and kill tumors (ICI) or by blocking the mechanisms that promote their growth (targeted mAbs), ElsaLys Biotech widens the range of combinations in oncology and in ophthalmology with strong potential therapeutic targets.

Expertise and Technological Skills

To drive its developments, the company relies on a robust academic international network, an internal R&D platform that covers from targets sourcing to clinical development of drug candidates and a team of experts with solid experience in immuno-oncology and antibodies development. Today, ElsaLys Biotech is advancing four R&D proprietary development programs in oncology and in ophthalmology.

Ongoing Collaboration and References

The different programs are conducted in collaboration with academic lab in Germany (M. Seiffert, V. Umansky DKZF), in France (Pr Mauvieux, Hautepiere Hospital, Strasbourg; C Caux, Centre Leon Bérard; S Germain, Collège de france; C Arndt, CHU Reims/Institut Jean Godinot), in the US (R Birge, State University of New Jersey), in the UK (F Mussai, University of Birmingham) and in Spain (D Benitez-Ribas, Hospital Clinic de Barcelona).

Sought Opportunities

The number of cancers is expected to increase dramatically over the next 20 years. Even though constant progress, some current treatments have limited efficacy, alone or in combination. Developing new, more specific and less toxic treatments could help to address these medical gaps, to overcome the resistance, to increase the therapeutic options for combination therapies and improve patients’ outcome and quality of life.
Activity

ElyssaMed® is developing an active immunotherapy against cancer, mainly non-small-cell lung cancer (NSCLC), but also neuroendocrine tumors (NET) and medullary thyroid carcinomas (MTC), which are classified as orphan diseases. This immunotherapy is based on five antigenic peptides derived from a tumor antigen, the preprocalcitonin (ppCT) antigen, and an adjuvant. It differs from all other concurrent immunotherapy approaches by its mode of action, which permit to overcome tumor escape from the immune system and thus its use in multi-resistant patients.

Expertise and Technological Skills

This cancer immunotherapy is based on the discovery of a new tumor antigen, the ppCT antigen. The team has demonstrated that ppCT is expressed in several human lung tumors and is able of inducing a specific antitumor immune response in many cancer patients. ppCT is characterized by the inclusion of a T-cell epitope processed by a novel mechanism that permits CD8 T-cell immunity to destroy immune-escaped tumors. The ultimate goal is to combine this immunotherapy with an immune checkpoint inhibitor (anti-PD-1) and with mutated peptides (neoepitopes) identified in each patient’s tumor for a more personalized therapeutic cancer vaccine.

Ongoing Collaboration and References

- Prof. Benjamin BESSE, Gustave Roussy; Prof. Pierre COULIE, ULB Bruxelles, Prof. PEDRO ROMERO, Ludwig Institutes Lausanne, Prof. Matthieu Montes (CNAM).

Sought Opportunities

Today we are looking for a financing support for our Phase 1b clinical trial. It could be a pharmaceutical company or a financial investor.
Activity

GamaMabs Pharma is a clinical-stage French immuno-oncology biotechnology company developing breakthrough antibody-based therapeutics. Gamamabs’ first-in-class proprietary therapeutic monoclonal antibodies have unique mechanism of action of killing tumor cells though the activation of immune cells. Its lead project is the first-in-class monoclonal antibody GM102 which targets AMHR2, currently tested in gynecological cancer patients.

Expertise and Technological Skills

Gamamabs has developed a unique know-how on both the AMHRII target and on immuno-enhancing antibodies (EMAbling® technology). AMHRII is an untapped target that is re-expressed in carcinogenesis in a wide range of solid tumors. EMAbling® technology enables antibodies to activate tumor-environment immune cells (macrophages and NK cells) and restore their ability to kill tumor cells.

Ongoing Collaboration and References

Gamamabs has developed a unique network of collaborations in Europe and in in the US with leading research centers and renown opinion leaders in oncology clinical research, such as Inserm, Institut Curie, Institut Gustave Roussy, IUC Toulouse, Mayo Clinic (US) and Mass General Hospital (US). GamaMabs has an industrial collaboration with LFB (France) on Emabling® technology.

Sought Opportunities

Gamamabs is searching for development collaborations with leading oncology Pharma on its GM102 drug, in particular in view of trying combinations trials combining GM102 with check point inhibitors.
**Activity**

GlioCure is a biotech company dedicated to the treatment of glioblastoma (GBM), the most frequent and aggressive brain tumor with a fatal outcome. GlioCure is currently focusing on the development of GC01, a first-in-class anti-mitotic peptide with a specific anti-glioblastoma activity, derived from its targeting and penetrating glioblastoma and brain-tumor-initiating cells proprietary platform (GlioVector).

**Expertise and Technological Skills**

GlioCure’s management team is composed of LM Bachelot (CEO), a serial biotech entrepreneur, and C Lépinoux-Chambaud (COO, Head of R&D), a neurosciences researcher, co-discoverer of GC01. Its SMAB gathers Dr. J Eyer, DR Inserm, main discoverer of GC01, Prof. ME Halatsch, Vice-Chair of the Neurosurgery Department at Ulm University, Dr. JP Bizarri, a world renowned expert in clinical oncology, and Dr. J Richard, Senior Vice-President Peptides Development at Ipsen Group.

**Ongoing Collaboration and References**

GC01 has been reviewed, selected and supported by the international board of MATWIN GlioCure is one of the four partners (with UMR Inserm 1066-CNRS 6021 Angers, ADDB Louvain Drug Research Institute and Faculty of Pharmacy Laval Uni, Québec) of the EuroNanoMed III Gliogel project that intends to develop a gel-based device composed of lipid nanocapsules vectorized by GlioVector for the controlled and sustained release of chemotherapeutic drugs within the resection cavity of glioblastoma tumors.

**Sought Opportunities**

GlioCure is looking for an industrial partner that can bring significant capacities and expertise regarding the manufacturing and regulatory submissions of anticancer drugs, to boost the preclinical development of GC01 and support the launch of a first-in-human study within three years.
**Activity**

HalioDx SAS is an immuno-oncology diagnostic company that designs and develops a unique range of immune scoring tests. By precisely measuring the immune reaction in and around the tumor, HalioDx tests allow the clinician to determine the degree of severity of the patient’s disease and predict the response to treatment, regardless of the cancer stage or the molecular class.

**Expertise and Technological Skills**

HalioDx was founded in 2014 as a spin-off of Qiagen-Marseille by a team of seasoned managers with an extensive track records in the cancer diagnostic field, and a pioneer in integrative immunology and oncology, Dr. Jérôme Galon. HalioDx benefits of worldwide licences on a broad portfolio of IP rights on immuno-oncology biomarkers. With an experienced team of more than 120 employees and US and CE regulatory compliant facilities, HalioDx develops, manufactures, delivers and markets IVD products and services in immuno-oncology.

**Ongoing Collaboration and References**

HalioDx collaborates with an increasing number of renowned international clinical groups like the Mayo Clinic in US, the French intergroup PRODIGE, Gustave Roussy Institute, to conduct clinical utility studies and ensure rigorous performance validation of its assays in a large number of cancer indications. HalioDx also collaborates with biopharmaceutical companies such as Lytix, Kite or Nanobiotix to support their biomarker strategy along with their clinical development programmes. Some of those collaborations are described in more details in our Press release section available on our website.

**Sought Opportunities**

The objective of the company is to:

- Develop Immunoscore® Colon as a standard in the management of stage II and III colon cancer
- Expand Immunoscore® and related assays to other cancer types and respond to unmet medical needs
- Empowering Pharma Companies with a comprehensive biomarker portfolio and technologies in order to support them in their companion diagnostics development.
Activity

H-IMMUNE is an emerging player in the field of immune-oncology (I/O). The company is deploying a proprietary highly-potentate discovery engine against novel first in class to build-up an early stage drug program pipeline to be solely developed or in partnership.

Expertise and Technological Skills

The key element of H-Immune’s core expertise is the leveraging of its proprietary In Vitro Immunization (IVI) platform, which has a unique ability to generate a series of fully human antibodies against the entire epitope mapping of any therapeutic target by taking advantage of the affinity maturation processes performed directly in situ by B lymphocytes.

Ongoing Collaboration and References

Academic Partners: CEA Saclay (Dr M. Leonetti, PhD), Gustave Roussy (Dr P. Busson, MD PhD)
Industrial Partners: Laboratoires Pierres Fabre, Northern Biologics

Sought Opportunities

- IVI-based antibody campaign partnership opportunities
- Co-development of early stage drug program against emerging first in class target in the I/O space.
Activity

ImCheck is developing two first-in-class immunomodulator antibodies and is advancing several discovery programs on undisclosed targets, which play a defined immune-modulating role in both innate and adaptive immunity. ImCheck is implementing new translational R&D approaches combining predictive biomarkers development, experimental models based on freshly isolated human tumor samples and long established partnerships with a network of world class scientists.

Expertise and Technological Skills

- Large panel of «checkpoint inhibitors» characterized by Olive’s team which represent an opportunity to by-pass resistances to anti-CTLA-4 and anti-PD-1 antibodies.
- Functional modulation of Tumor Infiltrating Lymphocytes isolated from fresh tumor samples
- CD4, CD8 and γδ-T cells immune research
- Preclinical and early clinical development expertise

Ongoing Collaboration and References

Academic collaboration with renowned institutions in the field of tumor immunology

Sought Opportunities

- Imcheck may enter into partnering discussion for its asset(s) in order to accelerate the development of the company:
- 2 assets in preclinical development (INDs in 2019) for IO and infections
- 1-2 candidates ready for preclinical development (autoimmunity, GVHD)
- Drug discovery pipeline (5 target validation program)
Inovactis has developed a genetically modified S. cerevisiae (yeast) immunotherapy to safely induce a targeted immune response against any cancer type. Through a patented technique, Inovactis engineers the yeast to produce specific tumor neoantigens and antibodies that modify in vivo the patient immune system. At present, Inovactis yeast platform technology is aiming at fighting metastatic melanoma and the colorectal cancer MSS in a personalized way. The melanoma treatment market is expected to reach €5 billion by 2023, while the colorectal cancer will reach €11 billion by 2025.

**Expertise and Technological Skills**

Inovactis technology relies on synthetic biology to create personalized yeast immunotherapy, and Inovactis co-founders are experts in the synthetic biology field.

Dr Jean-Jacques Garaud is Inovactis strategic advisor. He was previously director of Roche early development.

Carole Pottier Garaud is Inovactis pre-clinical project development director.

Pr Bruno Colombo, an expert in dendritic cells immunotherapy, is a scientific board member of Inovactis.

**Ongoing Collaboration and References**

Inovactis collaborates with the Curie Institute (Paris V) for its cancer in vivo trials.

Inovactis has a partnership with Traaser, a genomic data company located at Genopole, for the patient neoantigens discovery.

**Sought Opportunities**

Inovactis is looking for co-development opportunities of its personalized immunotherapy with the pharmaceutical industry or major drug biotech companies.
AMEDSENIC develops a medication for autoimmune diseases, based on a CNRS patent family, under an exclusive worldwide licence agreement. The drug- arsenic trioxide- has already an excellent record in terms of pharmacovigilance and safety in the field of cancer, is is being repositioned by MEDSENIC for chronic Graft-versus-host disease, systemic lupus erythematosus and systemic sclerosis. The development stage is now Phase II clinical studies at the national and international levels including positive preclinical and clinical Proofs of Concept, allowing further trials to firmly establish safety and efficacy of the treatment regimens.

Expertise and Technological Skills

MEDSENIC has three main fields of activity with corresponding skills and technical abilities:

- MEDSENIC now masters the GMP manufacturing and analysis techniques for aqueous preparations of its arsenic trioxide (Arscimed®) for intravenous injections,
- MEDSENIC has set up the preclinical experiments on animal models to evaluate precisely evaluate and discover the mode of action of arsenic salts at the cellular and molecular levels (specific immunoregulation and not immunosuppression),
- MEDSENIC controls its Phase II human clinical trials from protocol setup to validated statistical significance of data.

Ongoing Collaboration and References

Collaborations have been set up:

- with public and private laboratories expert in animal models, especially using mice, either genetically modified or pharmacologically treated,
- with CMOs (namely Pierre Fabre) for complex sterile manufacturing of its cytotoxic own production of injectable arsenic trioxide, named Arscimed®,
- with CROs (for GvHDc: Fovea/PopsiCube) for the follow up and monitoring of its Phase 2 studies,
- with consulting agencies specialized in reglementary (Voisin Consulting) and intellectual Properties affairs (Plasseraud Consulting).

Sought Opportunities

Industrial or capital venture partnership for clinical trials extensions and Market Access, in various medical applications in the autoimmunity field.
Activity

Nanobiotix is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to providing a new, more efficient treatment for cancer patients.

Expertise and Technological Skills

NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration. NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix's Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region. The Company has filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3.

Ongoing Collaboration and References

Not available at this time but in progress.

Sought Opportunities

Funding and collaboration with big pharma.
Activity

Novadiscovery is a professional services firm specialized in in silico clinical trials founded in Lyon, France in 2010. The company supports its biotech and pharma partners R&D programs through the upstream prediction of drug candidate efficacy by computer simulation long before human trials to improve R&D output.

Expertise and Technological Skills

The company combines experts in biology, mathematical modeling, computer science, clinical pharmacology and medicine. The company’s WISE technology (“Whitebox In Silico Engine”) combines a community-driven “knowledge engine” to curate and organize biomedical knowledge (GitHealth) with modeling & simulation “action engine” industrializing the company’s standard operating procedures (“SimWork”).

Ongoing Collaboration and References

The company has already successfully served big phamas and biotechs (Bristol-Myers Squibb in immuno-oncology, Sanofi…). We currently work with a handful of biotechs in various therapeutic areas. We are also part of an RHU project (PIONeeR) which is expected to launch by year-end in collaboration with academic centers in Marseille and AstraZeneca in immuno-oncology.

Sought Opportunities

The company intends to increase its visibility in the ecosystem via RIB 2018 with a view to expand its business development portfolio as well as engage with potential investors to support its scale-up phase.

Name of the company: NOVADISCOVERY
Name of the manager: François-Henri BOISSEL
Telephone: +33 (0)6 75 48 31 81
e-mail: francois.boissel@novadiscovery.com
Location: Lyon - FRANCE
OREGON THERAPEUTICS is a company developing XCE853, a “First in class” & “Best in class” drug candidate with an innovative and unique mechanism of action: Inhibition of Protein Disulfide Isomerase (PDI). OREGON THERAPEUTICS 1st objective is to bring the drug candidate XCE853 into clinical trial (Phase 1) for the treatment of human cancer within 2 years. Based on the scientific rationale, priority indication is advanced PANCREAS cancer.

Expertise and Technological Skills

A team of key managers with strong oncology backgrounds is working in cooperation with international centers of excellence in the field of oncology. This team of highly experienced key managers includes former pharma and biotech executives with successful track records. The breadth of experience includes R&D project management, operations and start-up experience.

Ongoing Collaboration and References

- Professor Nouri Neamati, University of Michigan, USA
- Dr Michèle Sabbah et Nathalie Ferrand – Hôpital Saint Antoine Paris, France
- Dr Catherine Brenner & Dr Claudine Deloménie, Université Paris-Sud, France
- National Cancer Institute (NCI) Bethesda, USA
- Dr Annemilai Raballand & Dr Armand de Gramont Groupe AFR, France
- Dr Anne Chauchereau & Dr Michele Mondini - Gustave Roussy, Villejuif, France
- Professor Paul Foster, University of Birmingham, England
- Professor Eric Raymond, Hôpital Saint Joseph, Université Paris Diderot, Paris, France

Sought Opportunities

The company’s short term aim is to create value by performing the Proof of Concept in human of this new drug to treat cancers. After completion of the first in man study, the phase II will allow to demonstrate the clinical benefit of XCE853. The “First in Class” positioning: Unique mechanism of action on a validated new target, with no direct competitors. Higher antitumor activity against cancers where the medical need is very high (i.e.: Pancreas, Ovarian, Head & Neck, Liver Cancers) - XCE853 is specifically active on drug-resistant tumor cells Combinations of XCE853 with chemotherapy or radiotherapy increase the antitumor benefit. Biomarkers of XCE853 early antitumor activity have been validated.
Activity

Stimunity develops new biopharmaceuticals based on Virus-Like Particles (VLP) to treat patients that do not respond to conventional immunotherapies in oncology (anti-checkpoint therapy).

Expertise and Technological Skills

Stimunity’s biopharmaceuticals are based on the VLP-cGAMP platform technology which activates the innate immune system via the STING pathway and induces T-cell response against tumor cells.

Ongoing Collaboration and References

- R&D collaboration with Institut Curie
- Laureate of the i-lab 2017 national competition
- Laureate of the Scientipôle Initiative in biotechnology
- 2016 Biovision Catalyzer Special Award

Sought Opportunities

- Seed investment of 2M€
- Co-development partnership
Activity

Theraclion is a pioneer in the therapeutic use of ultrasound (HIFU). Theraclion develops, manufactures, and markets the Echopulse® medical device for the non-invasive, outpatient treatment of breast fibroadenomas and benign thyroid nodules. Its clinical research activity is starting now in Cancer as FDA authorized first combined trial to treat stage 4 Breast cancer, combining pembroluzimab and HIFU.

Expertise and Technological Skills

Theraclion is currently the only company in the world offering a completely non-invasive treatment for breast fibroadenomas and benign thyroid nodules. It relies on ultrasound-guided high-intensity focused ultrasound for the thermo-ablation of tumor tissues.

Ongoing Collaboration and References

Theraclion is the first “Forfait Innovation”-approved to evaluate the medical-economic benefits of HIFU in a randomized control trial vs. surgical excision of benign breast tumors. Theraclion is also involved with the University of Virginia for the first-in-the-world test of a combined treatment of stage 4 metastatic breast cancer with HIFU and anti-PD1 checkpoint inhibitor pembrolizumab.

Sought Opportunities

Pioneer in therapeutic ultrasound, Theraclion could accelerate its oncology developments through an industry or financial partnership to strengthen its position in the highly promising immuno-oncology area.
THERAVECTYS, a privately-owned biotech company, translates 20+ years of research on lentiviral vectors into actionable innovation and delivers remarkably safe and highly efficient T-cell vaccines as a response to critical unmet medical needs. Leveraging its versatile technology, TheraVectys develops immunotherapies in a large number of applications in infectious diseases, virally-induced cancers and cancers.

**Expertise and Technological Skills**

Founded by pioneer inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys’ technological core skills lie in lentiviral vectors vaccines design, optimization and development. Today TheraVectys also benefits from a Joint-Lab with the Pasteur Institute, and therefore from the extensive experience of the technology founder in vaccine development, lentiviral vectors, and more broadly in infectiology.

**Ongoing Collaboration and References**

TheraVectys benefits from an on-campus R&D laboratory partnership (Joint Lab) with the Pasteur Institute, that ensures organic collaboration and synergies while it also continuously widens and enriches TheraVectys’ patent portfolio. Additionally, several co-development collaborations and sub-licensing deals are currently under advanced negotiation.

**Sought Opportunities**

TheraVectys is actively seeking partners for: (1) Co-development & collaboration for POC-validated vaccine candidates in infectious diseases; (2) Out-Licensing for POC-validated vaccine candidates for veterinary applications or out-licensing of broader veterinary vaccines rights; (3) Early Collaboration for our oncology developments in particular on tumor antigens discovery (neoantigens or pan-tumoral approaches).
Vaxeal develops advanced immunotherapies based on long synthetic peptides in combination with immunomodulatory drugs to meet the growing need for improved anti-cancer treatments. Our unique and innovative scientific research, and our improved understanding of immunological mechanisms, are at the heart of Vaxeal’s mission to deliver cutting-edge therapies. Vaxeal’s initial programs have reached the pre-clinical stage, and will enter into clinical trials in 2018.

Expertise and Technological Skills

Vaxeal’s innovative technology platforms and core expertise has allowed the management team to develop an optimal and innovative combined strategy for the design of cancer immunotherapies enabling to overcome both efficacy, safety, and immunosuppression issues encounter with current cancer immunotherapy approaches. This strategy is based on the synergistic combination of advanced therapeutic cancer vaccines with low doses of immune-checkpoint blockade therapies.

Ongoing Collaboration and References

Public-Private partnership is at the heart of Vaxeal’s product development strategy. Vaxeal has established strategic partnerships with leading European research institutions in healthcare, notably the with the life sciences department of the CEA. In collaboration with our partners, Vaxeal has also already obtained two grants for the development of its products. Vaxeal is also a member of two leading industrial bodies: European Biopharmaceutical Enterprises (EBE) and Vaccines Europe.

Sought Opportunities

By participating to RIB 2018, we expect to strengthen and accelerate our development by connecting to mentors, advisors and end-users. In addition, as we have successfully achieved our first milestones, consisting in the completion of ‘pre-clinical’ proof-of-concept stage on SVX-1, we are now looking to raise €7 million to complete our second major milestones, the Phase I/II of our most advanced cancer immunotherapy (SVX-1), and pre-clinical PoC of a second product (CBX-1).